Genzyme has released results from a Phase III trial of its Clolar medication, which it tested in conjunction with chemotherapy agent cytarabine as a treatment of relapsed-refractory adult acute myeloid leukaemia.

The study found that the Clolar combination demonstrated a statistical significance across all four pre-specified secondary efficacy endpoints, including overall remission rate.

Hagop Kantarjian of the Anderson Cancer Center also confirmed that the Clolar combination doubled the overall remission rate to 47% and improvedin event-free survival by 37%.

The study, conducted as a randomised, double-blind, placebo-controlled clinical trial, revealed no new safety signals or adverse events.